Authors:
Ree, AH
Engerbraaten, O
Hovig, E
Fodstad, O
Citation: Ah. Ree et al., Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: Gene expression profiles in bone marrow target cells, INT J CANC, 97(1), 2002, pp. 28-33
Authors:
Moller, P
Borg, A
Heimdal, K
Apold, J
Vallon-Christersson, J
Hovig, E
Maehle, L
Citation: P. Moller et al., The BRCA1 syndrome and other inherited breast or breast-ovarian cancers ina Norwegian prospective series, EUR J CANC, 37(8), 2001, pp. 1027-1032
Authors:
Wacey, AI
Cooper, DN
Liney, D
Hovig, E
Krawczak, M
Citation: Ai. Wacey et al., Disentangling the perturbational effects of amino acid substitutions in the DNA-binding domain of p53, HUM GENET, 104(1), 1999, pp. 15-22
Authors:
Borg, A
Dorum, A
Heimdal, K
Maehle, L
Hovig, E
Moller, P
Citation: A. Borg et al., BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations, DIS MARKER, 15(1-3), 1999, pp. 79-84
Authors:
Bjornland, K
Winberg, JO
Odegaard, OT
Hovig, E
Loennechen, T
Aasen, AO
Fodstad, O
Maelandsmo, GM
Citation: K. Bjornland et al., S100A4 involvement in metastasis: Deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme, CANCER RES, 59(18), 1999, pp. 4702-4708
Authors:
Dorum, A
Heimdal, K
Hovig, E
Inganas, M
Moller, P
Citation: A. Dorum et al., Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer, AM J HU GEN, 65(3), 1999, pp. 671-679
Authors:
Andersen, K
Maelandsmo, GM
Hovig, E
Fodstad, O
Loennechen, T
Winberg, JO
Citation: K. Andersen et al., Interleukin-1 alpha and basic fibroblast growth factor induction of matrixmetalloproteinases and their inhibitors in osteosarcoma cells is modulatedby the metastasis associated protein CAPL, ANTICANC R, 18(5A), 1998, pp. 3299-3303